← Human Trials & Peer-Reviewed Studies
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
Plain-language guide to PMID 30122305 (2018): double-blind randomized controlled trial study of Semaglutide and Liraglutide, fat loss, obesity & body recomposition.
Key Facts
- PMID
- 30122305
- Journal
- Lancet (London, England)
- Year
- 2018
- Study type
- Randomized Controlled Trial
- Authors
- O'Neil PM et al. (10 authors)
- DOI
- 10.1016/S0140-6736(18)31773-2
- Registered trial
- NCT04529278, NCT02453711
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Semaglutide and Liraglutide in the context of fat loss, obesity & body recomposition.
Who Took Part
The age groups tagged for this paper are adults and middle-aged adults, both men and women.
Eligible participants were adults (≥18 years) without diabetes and with a body-mass index (BMI) of 30 kg/m2 or more.
How the Study Was Run
The design is described as randomized, double-blind, placebo-controlled and multicenter.
Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.
Blinding on both sides kept the participants and researchers unaware of who received Semaglutide.
Some participants received a placebo instead of Semaglutide, giving a reference point.
More than one site took part, so the participants came from several places.
The study was done in eight countries involving 71 clinical sites.
The primary endpoint was percentage weight loss at week 52.
The primary analysis was done using intention-to-treat ANCOVA estimation with missing data derived from the placebo pool.
This study is registered with ClinicalTrials.gov, number NCT02453711.
What Was Measured
PubMed files the paper under topics including Blood Glucose, Body Mass Index, Glucagon-Like Peptide 1, Glucagon-Like Peptides, Glycated Hemoglobin, Hypoglycemic Agents and Liraglutide.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Semaglutide and Liraglutide in people with fat loss, obesity & body recomposition.
Its findings take up roughly 10 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2018 (Lancet (London, England)), a journal based in England.
More context: the Semaglutide compound page and the Liraglutide compound page, Fat loss, obesity & body recomposition research.
Our Notes on the Compounds
Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).
Liraglutide: A once-daily GLP-1 receptor agonist peptide; sold as Victoza for type 2 diabetes and Saxenda for weight management.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.